Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein

Journal of Virology

Volumn 90, Issue 4, 2016, Pages 1729-1740

  Wu, Yun Li ^a,b   Peng, Xian E ^a   Zhu, Yi Bing ^a   Yan, Xiao Li ^a   Chen, Wan Nan ^a,b   Lina, Xu ^a,b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b Fujian Key Laboratory of Translational Cancer Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; HEPATITIS B VIRUS X PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FABP1 PROTEIN, HUMAN; LUCIFERASE; TRANSACTIVATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; FAT CONTENT; FATTY LIVER; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; HEPATITIS B; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; VIRUS LOAD; ANIMAL; BIOSYNTHESIS; COMPLICATION; DISEASE MODEL; GENE EXPRESSION PROFILING; GENE FUSION; GENETICS; HEP-G2 CELL LINE; HOST PATHOGEN INTERACTION; IMMUNOPRECIPITATION; LIVER CELL; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSGENIC MOUSE; VIROLOGY; WESTERN BLOTTING;

ANIMALS; ARTIFICIAL GENE FUSION; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; FATTY ACID-BINDING PROTEINS; FATTY LIVER; GENE EXPRESSION PROFILING; GENES, REPORTER; HEP G2 CELLS; HEPATITIS B; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOPRECIPITATION; LUCIFERASES; MALE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS;

EID: 84958093490     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02604-15     Document Type: Article

References (49)

1. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576. http: //dx.doi.org/10.1053/j.gastro.2007.04.061.
2. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. 2005. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution, and effect on fibrosis. J Hepatol 43:38-44. http://dx.doi.org/10.1016/) .jhep.2005.01.031.
3. Yoon EJ, Hu KQ. 2006. Hepatitis C virus (HCV) infection and hepatic steatosis. Int J Med Sci 3:53-56.
4. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, Kim HH, Yang US, Yu DY, Cheong J. 2007. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARα. Gastroenterology 132:1955-1967. http://dx.doi.org/10.1053Zj.gastro.2007.03.039.
5. Kang SK, Chung TW, Lee JY, Lee YC, Morton RE, Kim CH. 2004. The hepatitis B virus X protein inhibits secretion of apolipoprotein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem /279:28106-28112. http://dx.doi.org/10.1074/jbc.M403176200.
6. Huang Q, Wang L, Bai S, Lin W, Chen W, Lin J, Lin X. 2009. Global proteome analysis of hepatitis B virus expressing human hepatoblastoma cell line HepG2. J Med Virol 81:1539-1550. http://dx.doi.org/10.1002 /jmv.21593.
7. Hertzel AV, Bernlohr DA. 2000. The mammalian fatty acid-binding protein multigene family: molecular and genetic insights into function. Trends Endocrinol Metab 11:175-180. http://dx.doi.org/10.1016/S1043
8. Zimmerman AW, Veerkamp JH. 2002. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 59:10961116. http://dx.doi.org/10.1007/s00018-002-8490-y.
9. Storch J, Corsico B. 2008. The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr 28:73-95. http: //dx.doi.org/10.1146/annurev.nutr.27.061406.093710.
10. Wolfrum C, Ellinghaus P, Fobker M, Seedorf U, Assmann G, Borchers T, Spener F. 1999. Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. J Lipid Res 40:708-714.
11. Gibbons GF. 1994. A comparison of in-vitro models to study hepatic lipid and lipoprotein metabolism. Curr Opin Lipidol 5:191-199. http://dx.doi .org/10.1097/00041433-199405030-00006.
12. Schroeder F, Jolly CA, Cho TH, Frolov A. 1998. Fatty acid binding protein isoforms: structure and function. Chem Phys Lipids 92:1-25. http: //dx.doi.org/10.1016/S0009-3084(98)00003-6.
13. Sorof S. 1994. Modulation of mitogenesis by liver fatty acid binding protein. Cancer Metastasis Rev 13:317-336. http://dx.doi.org/10.1007 /BF00666102.
14. Schroeder F, Atshaves BP, Starodub O, Boedeker AL, Smith RR 3rd, Roths JB, Foxworth WB, Kier AB. 2001. Expression of liver fatty acid binding protein alters growth and differentiation of embryonic stem cells. Mol Cell Biochem 219:127-138. http://dx.doi.org/10.1023 /A:1010851130136.
15. Wolfrum C, Buhlmann C, Rolf B, Borchers T, Spener F. +1999. Variation of liver-type fatty acid binding protein content in the human hepatoma cell line HepG2 by peroxisome proliferators and antisense RNA affects the rate of fatty acid uptake. Biochim Biophys Acta /1437:194-201. http://dx .doi.org/10.1016/S1388-1981(99)00008-6.
16. Linden D, Lindberg K, Oscarsson J, Claesson C, Asp L, Li L, Gustafsson M, Boren J, Olofsson SO. +2002. Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. J Biol Chem /277: 23044-23053. http://dx.doi.org/10.1074/jbc.M110416200.
17. Gao N, Qu X, Yan J, Huang Q, Yuan HY, Ouyang DS. 2010. L-FABP T94A decreased fatty acid uptake and altered hepatic triglyceride and cholesterol accumulation in Chang liver cells stably transfected with L-FABP. Mol Cell Biochem 345:207-214. http://dx.doi.org/10.1007/s11010-010 -0574-7.
18. Newberry EP, Xie Y, Kennedy S, Han X, Buhman KK, Luo J, Gross RW, Davidson NO. 2003. Decreased hepatic triglyceride accumulation and altered fatty acid uptake in mice with deletion of the liver fatty acid-binding protein gene. J Biol Chem 278:51664-51672. http://dx.doi.org/10 .1074/jbc.M309377200.
19. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. 2006. Protection against Western diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein knockout mice. Hepatology 44:1191-1205. http://dx.doi.org/10.1002/hep.21369.
20. Newberry EP, Kennedy SM, Xie Y, Luo J, Davidson NO. 2009. Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice. Mol Cell Biochem 326:79-86. http://dx.doi.org/10.1007/s11010-008-0002-4.
21. Wu YL, Peng XE, Wang D, Chen WN, Lin X. 2012. Human liver fatty acid binding protein (hFABP1) gene is regulated by liver-enriched transcription factors HNF3β and C/EBPα. Biochimie 94:384-392. http://dx .doi.org/10.1016/j.biochi.2011.08.006.
22. Lin YJ, Huang LR, Yang HC, Tzeng HT, Hsu PN, Wu HL, Chen PJ, Chen DS. 2010. Hepatitis B virus core antigen determines viral persistencein a C57BL/6 mouse model. Proc Natl Acad Sci U S A 107:9340-9345. http://dx.doi.org/10.1073/pnas.1004762107.
23. Wu YL, Wang D, Peng XE, Chen YL, Zheng DL, Chen WN, Lin X. 2013. Epigenetic silencing ofNAD(P)H:quinone oxidoreductase 1 byhepatitis B virus X protein increases mitochondrial injury and cellular susceptibility to oxidative stress in hepatoma cells. Free Radic Biol Med 65:632644. http://dx.doi.org/10.1016/j.freeradbiomed.2013.07.037.
24. Wu BK, Li CC, Chen HJ, Chang JL, Jeng KS, Chou CK, Hsu MT, Tsai TF. 2006. Blocking of G1/S transition and cell death in the regenerating liver ofhepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 340:916-928. http://dx.doi.org/10.1016/j.bbrc.2005.12.089.
25. Chen X, Calvisi DF. 2014. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am J Pathol 184:912-923. http://dx.doi.org/10.1016/j.ajpath.2013.12.002.
26. Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Cas-tell JV, O'Connor JE. 2007. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165:106-116. http://dx.doi.org /10.1016/j.cbi.2006.11.004.
27. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, McClain CJ. 2007. Palmitic acid induces production of proin-flammatorycytokine interleukin-8 from hepatocytes. Hepatology 46:823-830. http://dx.doi.org/10.1002/hep.21752.
28. Sells MA, Chen ML, Acs G. 1987. Production ofhepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 84:1005-1009. http://dx.doi.org/10.1073/pnas.84.4.1005.
29. Newberry EP. 2009. Liver fatty acid binding protein (L-FABP) as a target for the prevention of high-fat diet induced obesity and hepatic steatosis immunity. Endocrinol Metab Agents Med Chem 9:30-37.
30. Guzman C, Benet M, Pisonero-Vaquero S, Moya M, Garcia-Mediavilla MV, Martinez-Chantar ML, Gonzalez-Gallego J, Castell JV, Sanchez-Campos S, Jover R. 2013. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα and repressed by C/EBPα: implications in FABP1 down-regulation in nonalcoholic fatty liver disease. Biochim Biophys Acta /1831:803-818. http://dx.doi.org/10 .1016/j.bbalip.2012.12.014.
31. Adams LA, Lindor KD. 2007. Nonalcoholic fatty liver disease. Ann Epidemiol 17:863-869. http://dx.doi.org/10.1016/j.annepidem.2007.05.013.
32. Powell EE, Jonsson JR, Clouston AD. 2005. Steatosis: co-factor in other liver diseases. Hepatology 42:5-13. http://dx.doi.org/10.1016/j.jhep.2004 .11.007.
33. Browning JD, Horton JD. 2004. Molecular mediators ofhepatic steatosis and liver injury. J Clin Invest 114:147-152. http://dx.doi.org/10.1172 /JCI200422422.
34. Bouchard MJ, Schneider RJ. 2004. The enigmatic X gene of hepatitis B virus. J Virol 78:12725-12734. http://dx.doi.org/10.1128/JVI.78.23.12725 -12734.2004.
35. Bouchard MJ, Wang L, Schneider RJ. 2006. Activation of focal adhesion kinase by hepatitis B virus HBx protein: multiple functions in viral replication. J Virol 80:4406-4414. http://dx.doi.org/10.1128/JVI.80.9.4406 -4414.2006.
36. Tang H, Oishi N, Kaneko S, Murakami S. 2006. Molecular functions and biological roles ofhepatitis B virus X protein. Cancer Sci 97:977-983. http: //dx.doi.org/10.1111/j.1349-7006.2006.00299.x.
37. Rui E, Moura PR, Goncalves KA, Rooney RJ, Kobarg J. 2006. Interaction of the hepatitis B virus protein HBx with the human transcription regulatory protein p120E4F in vitro. Virus Res 115:31-42. http://dx.doi .org/10.1016/j.virusres.2005.07.003.
38. Barnabas S, Andrisani OM. 2000. Different regions ofhepatitis B virus X protein are required for enhancement of bZip-mediated transactivation versustransrepression.JVirol 74:83-90. http://dx.doi.org/10.1128/JVI.74 .1.83-90.2000.
39. Benn J, Su F, Doria M, Schneider RJ. 1996. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signalregulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 70:4978-4985
40. Su F, Schneider RJ. 1996. Hepatitis B virus HBx protein activates transcription factor NF-kB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol 70:4558-4566.
41. Samadani U, Costa RH. 1996. The transcriptional activator hepatocyte nuclear factor 6 regulates liver gene expression. Mol Cell Biol 16:62736284. http://dx.doi.org/10.1128/MCB.16.11.6273.
42. Schrem H, Klempnauer J, Borlak J. 2004. Liver-enriched transcription factors in liver function and development. II. The C/EBPs and D site-binding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol Rev 56:291-330.
43. Antonson P, Xanthopoulos KG. 1995. Molecular cloning, sequence, and expression patterns ofthe human gene encoding CCAAT/enhancer binding protein alpha (C/EBPa). Biochem Biophys Res Commun 215:106113. http://dx.doi.org/10.1006/bbrc.1995.2439.
44. Crosson SM, Davies GF, Roesler WJ. 1997. Hepatic expression of CCAAT/enhancer binding protein alpha: hormonal and metabolic regulation in rats. Diabetologia 40:1117-1124. http://dx.doi.org/10.1007 /s001250050796.
45. Diehl AM, Yang SQ. 1994. Regenerative changes in C/EBP alpha and C/EBP beta expression modulate binding to the C/EBP site in the c-fos promoter. Hepatology 19:447-456. http://dx.doi.org/10.1002/hep .1840190225.
46. Diehl AM, Michaelson P, Yang SQ. 1994. Selective induction of CCAAT/ enhancer binding protein isoforms occurs during rat liver development. Gastroenterology 106:1625-1637.
47. Storch J, McDermott L. 2009. Structural and functional analysis of fatty acid-binding proteins. J Lipid Res 50(Suppl):S126-S131.
48. Barter PJ, Rye KA. 2006. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Circulation 113:1553-1555. http://dx.doi.org/10.1161/circulationaha.105.620450.
49. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. 1999. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 103:1489-1498. http://dx.doi .org/10.1172/JCI6223.